News FibroGen, Inc.

Equities

FGEN

US31572Q8087

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
0.9843 ^USD	-8.01%		-24.28%	+11.06%

Apr. 15	Faron Pharmaceuticals reappoints former finance chief on interim basis	AN
Apr. 03	Top Midday Decliners	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting	Apr. 24	AQ
Faron Pharmaceuticals reappoints former finance chief on interim basis	Apr. 15	AN
Top Midday Decliners	Apr. 03	MT
FibroGen Says Phase 1 Study of Potential Prostate Cancer Treatment Shows Promise	Apr. 03	MT
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer	Apr. 02	AQ
Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer	Apr. 02	CI
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference	Mar. 26	AQ
FibroGen : Corporate Presentation – March 2024	Mar. 19	PU
Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 12	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	Mar. 12	MT
FibroGen Shares Jump After CEO Stock Purchase	Mar. 12	MT
FibroGen Names Deyaa Adib Chief Medical Officer	Mar. 11	MT
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer	Mar. 11	AQ
FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer	Mar. 11	CI
FibroGen : Corporate Presentation – March 2024	Mar. 06	PU
FibroGen: Q4 Earnings Snapshot	Feb. 26	AQ
Transcript : FibroGen, Inc., Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26
FibroGen regains rights to anemia drug from AstraZeneca	Feb. 26	RE
FibroGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Earnings Flash (FGEN) FIBROGEN Reports Q4 Revenue $27.1M, vs. Street Est of $38.8M	Feb. 26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News FibroGen, Inc.

Equities

FGEN

US31572Q8087

Summary

Filters